Universitätsklinikum Heidelberg
Heidelberg, Germany
24 recruiting
Showing 1–20 of 50 trials
Recruiting
Phase 3
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
Systemic Sclerosis
Boehringer Ingelheim448 enrolledNCT07497087
Recruiting
Phase 2
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company65 enrolled40 locationsNCT07015242
Recruiting
Phase 3
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
Chronic Kidney Disease
Boehringer Ingelheim120 enrolled102 locationsNCT07107945
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Solid TumorsHGGCancer Harboring BRAF Alterations+1 more
Fore Biotherapeutics254 enrolled70 locationsNCT05503797
Recruiting
Phase 3
Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL
Hospital-Acquired PneumoniaCommunity-acquired PneumoniaVentilator associated pneumonia+2 more
Jena University Hospital616 enrolled28 locationsNCT06134492
Recruiting
Not Applicable
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
Deep Venous ThrombosisVenous ThromboembolismPost Thrombotic Syndrome
Inari Medical300 enrolled64 locationsNCT05701917
Recruiting
Phase 3
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis
Boehringer Ingelheim286 enrolled296 locationsNCT07220083
Recruiting
Phase 4
Toric Performance And Constant Evaluation
Cataract
Carl Zeiss Meditec AG130 enrolled6 locationsNCT07471295
Recruiting
Phase 3
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Extrapulmonary Neuroendocrine Cancer (epNEC)
Boehringer Ingelheim390 enrolled165 locationsNCT07544654
Recruiting
Phase 2
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Inflammatory Bowel DiseasesCrohn's Disease
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)385 enrolled225 locationsNCT06226883
Recruiting
Phase 1Phase 2
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Multiple MyelomaPlasma Cell Disorder
Heidelberg Pharma AG78 enrolled24 locationsNCT04879043
Recruiting
Phase 3
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Eli Lilly and Company190 enrolled79 locationsNCT03773965
Recruiting
Phase 2
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Breast Cancer
Hoffmann-La Roche60 enrolled33 locationsNCT07054190
Recruiting
Phase 3
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Metabolic dysfunction-associated steatohepatitis (MASH)Liver Fibrosis
Boehringer Ingelheim1,800 enrolled525 locationsNCT06632444
Recruiting
Phase 3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Metabolic Dysfunction-Associated Steatohepatitis
Boehringer Ingelheim1,590 enrolled444 locationsNCT06632457
Recruiting
Phase 1Phase 2
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
ALK Fusion-positive Solid or CNS Tumors
Hoffmann-La Roche42 enrolled33 locationsNCT04774718
Recruiting
Treatment Guided by Comprehensive Genome and Transcriptome Analysis Versus Standard of Care in Advanced Rare Cancers
Rare Cancer
German Cancer Research Center946 enrolled16 locationsNCT06855134
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Moderately to Severely Active Crohns Disease
Hoffmann-La Roche425 enrolled187 locationsNCT06819891
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche350 enrolled200 locationsNCT06588855
Recruiting
Phase 3
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
Chronic Kidney DiseaseProteinuriaChildren
Bayer100 enrolled179 locationsNCT05457283